Loading
Life sciences · Journal article
Molecular Medicine · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
For decades, platinum resistance has remained one of the major barriers to improving outcomes in ovarian cancer. Patients with platinum-resistant ovarian cancer (PROC) generally have shorter overall survival and lower response rates to second-line treatment than those with platinum-sensitive disease. In recent years, innovative therapeutics have emerged for PROC, including antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), DNA-damage response (DDR) agents, and other rational combination regimens. However, a clinically oriented review integrating the biological basis and clinical applications of these approaches is still lacking. In this review, we summarize the evolving therapeutic landscape of PROC from the following perspectives: (1) the current mechanisms underlying platinum resistance, (2) ADCs targeting FRɑ, HER2, TROP2, CDH6, and other cell surface antigens, (3) immune checkpoint inhibitors and emerging immunotherapy-based combinations, (4) therapeutic strategies targeting the DNA damage repair pathway, (5) anti-angiogenic therapies, and (6) other investigational approaches. We integrate the preclinical and clinical evidence, with particular emphasis on treatment efficacy, patient selection, and targeted biomarkers. By connecting mechanistic insights with clinical development, this review aims to provide a practical framework for treatment decision-making and to identify priorities for future translational research in PROC.